Next Article in Journal
Recovery from Severe COVID-19 Is an Independent Predictor of Electrocardiographic Abnormal P-Wave Axis
Next Article in Special Issue
Prognostic Value of CRP/25 OH Vitamin D Ratio for Glucocorticoid Efficacy in Acute Severe Ulcerative Colitis Patients
Previous Article in Journal
Machine Learning for Predicting Biologic Agent Efficacy in Ulcerative Colitis: An Analysis for Generalizability and Combination with Computational Models
Previous Article in Special Issue
Machine Learning for Short-Term Mortality in Acute Decompensation of Liver Cirrhosis: Better than MELD Score
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 14
Issue 13
10.3390/diagnostics14131325
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B

by
Supakorn Chaiwiriyawong
1,
Suraphon Assawasuwannakit
2,
Poorikorn Feuangwattana
3,
Pimsiri Sripongpun
3,
Naichaya Chamroonkul
3,
Teerha Piratvisuth
4 and
Apichat Kaewdech
3,*
1
Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
2
Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand
3
Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
4
NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Songkhla 90110, Thailand
*
Author to whom correspondence should be addressed.
Diagnostics 2024, 14(13), 1325; https://doi.org/10.3390/diagnostics14131325
Submission received: 29 May 2024 / Revised: 16 June 2024 / Accepted: 20 June 2024 / Published: 22 June 2024
(This article belongs to the Special Issue Diagnosis and Management of Liver Diseases and Inflammatory Bowel Diseases)
Browse Figures
Versions Notes

Abstract

This study aimed to evaluate the efficacy of the aMAP score and compare it with other risk scores for predicting hepatocellular carcinoma (HCC) development in Thai patients with chronic hepatitis B (CHB). We retrospectively analyzed patients with CHB between 1 January 2008 and 31 December 2019. Data on demographics, clinical parameters, cirrhosis status, HCC imaging, and alpha fetoprotein surveillance were collected to calculate the aMAP score (0–100) based on age, sex, albumin–bilirubin level, and platelet count. Of the 1060 patients analyzed, 789 were eligible, of whom 51 developed HCC. The cumulative HCC incidences in the low-, moderate-, and high-risk groups at 3, 5, and 10 years were significantly different (log-rank, p < 0.0001). The area under the receiver operating characteristic curves (AUROCs) of the aMAP scores for predicting HCC at 3, 5, and 10 years were 0.748, 0.777, and 0.784, respectively. Among the risk scores, the CU-HCC score had the highest AUROCs (0.823) for predicting 5-year HCC development. The aMAP score is a valuable tool for predicting HCC risk in Thai patients with CHB and can enhance surveillance strategies. However, its performance is inferior to that of the CU-HCC score, suggesting the need for new predictive tools for HCC surveillance.
Keywords: HCC; aMAP score; chronic hepatitis B; surveillance; Thailand HCC; aMAP score; chronic hepatitis B; surveillance; Thailand

Share and Cite

MDPI and ACS Style

Chaiwiriyawong, S.; Assawasuwannakit, S.; Feuangwattana, P.; Sripongpun, P.; Chamroonkul, N.; Piratvisuth, T.; Kaewdech, A. Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. Diagnostics 2024, 14, 1325. https://doi.org/10.3390/diagnostics14131325

AMA Style

Chaiwiriyawong S, Assawasuwannakit S, Feuangwattana P, Sripongpun P, Chamroonkul N, Piratvisuth T, Kaewdech A. Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. Diagnostics. 2024; 14(13):1325. https://doi.org/10.3390/diagnostics14131325

Chicago/Turabian Style

Chaiwiriyawong, Supakorn, Suraphon Assawasuwannakit, Poorikorn Feuangwattana, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth, and Apichat Kaewdech. 2024. "Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B" Diagnostics 14, no. 13: 1325. https://doi.org/10.3390/diagnostics14131325

APA Style

Chaiwiriyawong, S., Assawasuwannakit, S., Feuangwattana, P., Sripongpun, P., Chamroonkul, N., Piratvisuth, T., & Kaewdech, A. (2024). Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. Diagnostics, 14(13), 1325. https://doi.org/10.3390/diagnostics14131325

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop